| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 100 | 120 | 110 | 120 | 110 |
| Sales Growth | -16.67% | +9.09% | -8.33% | +9.09% | +22.22% |
| Net Income | -520 | 370 | -1,400 | -230 | -260 |
| Net Income Growth | -240.54% | +126.43% | -508.70% | +11.54% | +29.73% |
Nutra Pharma Corp (NPHC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company operates through its subsidiaries and carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma currently offers several drug products for sale for the treatment of pain: Cobroxin, the over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the non-narcotic and non-addictive treatment for severe (Stage 3) pain. In addition, the Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases. Nutra Pharma Corporation is based in Boca Raton, Florida.
Fiscal Year End Date: 12/31